君实生物:拟用不超24亿元闲置募资进行现金管理
Xin Lang Cai Jing·2025-11-27 08:50

Core Viewpoint - The company plans to utilize up to 2.4 billion yuan of temporarily idle raised funds for cash management, with a validity period of 12 months, allowing for rolling use of the funds [1] Group 1: Fund Management - The board of directors approved the use of idle funds from a specific A-share issuance in 2022, totaling 3.777 billion yuan raised, with a net amount of 3.745 billion yuan as of June 30, 2025 [1] - The company intends to invest in capital-preserving products, ensuring that the investment does not affect the implementation of fundraising projects [1] Group 2: Financial Strategy - The priority of the returns will be to replenish project funds and supplement working capital, with the funds to be returned to a designated account upon maturity [1]